FDA Panel Set to Review GRAIL Multi-Cancer Blood Test
The FDA is preparing to review GRAIL’s Galleri multi-cancer blood test, a technology designed to detect signals from many cancers through one blood sample soon.
The FDA is preparing to review GRAIL’s Galleri multi-cancer blood test, a technology designed to detect signals from many cancers through one blood sample soon.
FDA is seeking public feedback on regulating generative AI-enabled medical devices while balancing innovation, clinical evidence, cybersecurity, and patient safety for doctors and patients nationwide.
Biotech company uniQure has applied for U.S. approval of an experimental Huntington’s gene therapy after FDA reversed an earlier position on its development this year.
FDA added a boxed warning to Injectafer labeling over low blood phosphate risks, advising monitoring for patients receiving repeat courses or facing risk factors closely.